Source: Overseas Network
Overseas Network, May 18 On the 17th local time, France's Sanofi Pharmaceutical Group announced the results of the second phase of the clinical trial of the new crown vaccine jointly developed with GlaxoSmithKline Pharmaceuticals in the UK, and said the data was encouraging.
According to AFP , Thomas Trimfe, executive vice president of vaccine affairs of Sanofi Group, said at a press conference that this phase of clinical trials conducted on 722 volunteers over 18 years old in the United States, Honduras and Panama showed that adults will produce high concentrations of neutralizing antibodies after one dose of vaccine. In all age groups, this antibody level is comparable to those who recover from COVID-19 infection.
At present, many of the new crown vaccines that have been released have overall effectiveness of more than 90%. The effectiveness of Sanofi , the recombinant protein vaccine, will be available in the third phase of clinical trials. However, the results of the second phase of the clinical trial showed that the immune response after injection of the vaccine was very good, and 95% to 100% of volunteers would produce new coronary antibodies after vaccination.
Sanofi will launch the third phase of clinical trials on more than 35,000 volunteers in the coming weeks, with the goal of putting the vaccine on the market in the fourth quarter of this year. At the same time, Sanofi is also studying different vaccine formulas for , a mutated new coronavirus.
Olivier Bogilot, president of Sanofi Group France, said in an interview with Europe One Radio on the 17th that Sanofi's research on the new crown vaccine has taken an important step. He stressed that although the Sanofi vaccine is late, its effectiveness is unquestionable and Sanofi will be committed to providing vaccines to the world.
Sanofi is facing a huge challenge and must work hard to catch up with the progress in this COVID-19 vaccination work. Currently, EU has approved the use of Pfizer , Moderna, AstraZeneca and Johnson & Johnson vaccines. Competition will be even more intense if the Sanofi vaccine can be launched in the fourth quarter of this year, but it will also help curb the rise in vaccine prices. Sources said the Sanofi vaccine should start pre-orders in the coming weeks, with a unit price of around 10 euros, which is almost half the price of Pfizer's recent renewal of the EU contract with the EU. (Overseas Network-Paris-Lujia)
Copyright works on Overseas Network are not allowed to be reproduced without authorization.
